Conclusions
Upadacitinib 15 mg QD demonstrated sustained improvement up to week 52 in bDMARD-IR patients with active AS during open-label treatment. Similar efficacy was observed at week 52 in patients on continuous upadacitinib and those who switched from placebo to upadacitinib 15 mg QD at week 14. Treatment with upadacitinib 15 mg QD was generally safe and well tolerated, with no new safety risks identified compared with the known safety profile of upadacitinib. The efficacy of upadacitinib 15 mg QD was generally similar across subgroups of patients who had discontinued prior bDMARD treatment due to lack of efficacy versus intolerance, and prior TNFi versus IL-17i exposure, and consistent with the overall SELECT-AXIS 2 bDMARD-IR AS population. These data suggest that upadacitinib is an effective treatment for bDMARD-IR patients with AS up to 1 year of treatment.